Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.

The expression of secreted protein acidic and rich in cysteine (SPARC) has been associated with the malignant progression of different types of human cancer. SPARC was associated with tumor cell capacity to migrate and invade, although its precise role in tumor progression is still elusive. In the present study, we show that SPARC produced by melanoma cells modulates the antitumor activity of polymorphonuclear leukocytes (PMN). Administration to nude mice of human melanoma cells in which SPARC expression was transiently or stably knocked down by antisense RNA (SPARC-sup cells) promoted PMN recruitment and obliterated tumor growth even when SPARC-sup cells accounted for only 10% of injected malignant cells. In addition, SPARC-sup cells stimulated the in vitro migration and triggered the antimelanoma cytotoxic capacity of human PMN, an effect that was reverted in the presence of SPARC purified from melanoma cells or by reexpressing SPARC in SPARC-sup cells. Leukotrienes, interleukin 8, and growth-related oncogene, in combination with Fas ligand and interleukin 1, mediated SPARC effects. These data indicate that SPARC plays an essential role in tumor evasion from immune surveillance through the inhibition of the antitumor PMN activity.

[1]  E. Sage,et al.  Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells , 2005, Journal of cellular physiology.

[2]  E. Sage,et al.  SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.

[3]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[4]  William P Schiemann,et al.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.

[5]  D. Bigner,et al.  Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model* , 2003, The Journal of Biological Chemistry.

[6]  M. Lagarde,et al.  Platelets may inhibit leucotriene biosynthesis by human neutrophils at the integrin level , 2003, British journal of haematology.

[7]  R. Brekken,et al.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.

[8]  C. Berking,et al.  Differential response of primary and metastatic melanomas to neutrophils attracted by IL‐8 , 2003, International journal of cancer.

[9]  N. Lemke,et al.  Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.

[10]  叶萍,et al.  β , 2002 .

[11]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[12]  D. Livant,et al.  Monocyte-Fibronectin Interactions, Via α5β1 Integrin, Induce Expression of CXC Chemokine-Dependent Angiogenic Activity1 , 2001, The Journal of Immunology.

[13]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[14]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[15]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[16]  F. Shanahan,et al.  Immune privilege or inflammation? Insights into the Fas ligand enigma , 2001, Nature Medicine.

[17]  P. Musiani,et al.  The intriguing role of polymorphonuclear neutrophils in antitumor reactions. , 2001, Blood.

[18]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[19]  R. Savani,et al.  Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[20]  W. Couser,et al.  SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[21]  M. Ringuette,et al.  Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. , 1999, Gynecologic oncology.

[22]  M. Webber,et al.  Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. , 1999, Cancer research.

[23]  E. Sage,et al.  Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[24]  T. Mikkelsen,et al.  Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.

[25]  C. Van Waes,et al.  The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. , 1999, Cancer research.

[26]  F. Dallegri,et al.  Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.

[27]  S. Rempel,et al.  SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G. Nabel,et al.  Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.

[29]  S. Nagata,et al.  Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.

[30]  M. Burdick,et al.  Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression , 1997, Journal of leukocyte biology.

[31]  K. Ikai,et al.  Human melanoma cells generate leukotrienes B4 and C4 from leukotriene A4 , 1997, Archives of Dermatological Research.

[32]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[33]  O. Podhajcer,et al.  The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.

[34]  R. Garofalo,et al.  Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation , 1996, Journal of virology.

[35]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[36]  R. Berkowitz,et al.  SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.

[37]  A. Anichini,et al.  Interaction with fibronectin regulates cytokine gene expression in human melanoma cells , 1996, International journal of cancer.

[38]  P. Chambon,et al.  Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours , 1996 .

[39]  J. Gershenwald,et al.  Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. , 1995, Cancer research.

[40]  H. Schreiber,et al.  Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.

[41]  H. Mitani,et al.  Human melanoma cells generate leukotriene B and C from leukotriene A , 1994 .

[42]  A. Issekutz,et al.  VLA-4 integrin can mediate CD11/CD18-independent transendothelial migration of human monocytes. , 1993, The Journal of clinical investigation.

[43]  M. Iruela-Arispe,et al.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.

[44]  P. Prasit,et al.  Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors. , 1991, The Journal of biological chemistry.

[45]  M. Walport,et al.  Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. , 1989, The Journal of clinical investigation.

[46]  J. Schröder,et al.  Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. , 1987, Journal of immunology.

[47]  M. Paulsson,et al.  Calcium binding domains and calcium-induced conformational transition of SPARC/BM-40/osteonectin, an extracellular glycoprotein expressed in mineralized and nonmineralized tissues. , 1987, Biochemistry.

[48]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[49]  L. Coussens,et al.  Inflammatory Cells and Cancer: Think Different! , 2001 .

[50]  Robert D. Goldman,et al.  Cells: a laboratory manual , 1997 .

[51]  L. Enquist,et al.  Protocols for gene transfer in neuroscience : towards gene therapy of neurological disorders , 1996 .

[52]  R. T. Oliver,et al.  The immunological aspects of malignant disease. , 1975, The Practitioner.

[53]  L. J. Reed A simple method of estimating fifty per cent end-points. , 1938 .